Dr. Martín is Head of the Department of Clinical Oncology at the Gregorio Marañón General University Hospital and Professor of Medicine at the Faculty of Medicine of the Complutense University, both located in Madrid, Spain. He is also President of GEICAM and one of its founding members. He is well known for his activity in the development of new medical methods and his participation as principal investigator in national and foreign clinical trials. He has 250 articles in magazines and books with a cumulative effect of 1042 and a h. -index of 26.
Dr. Eva Carrasco, Scientific Director and CEO of GEICAM and author of more than 70 peer-reviewed original papers in international scientific journals, commented, “The FLAMINGO-01 study is an example of the importance of alliances between the academic field and the pharmaceutical industry and of international collaboration. All this favors the implementation of studies that incorporate the perspective of clinicians from their conception, which represents a boost to breast cancer research and the development of new drugs for the benefit of patients.”
Dr. Luis de los Ángeles Cruz Merino, National Principal Investigator for Spain of FLAMINGO-01, commented: “The FLAMINGO-01 trial includes patients with high-risk HER2 breast cancer who have undergone popular adjuvant treatment and have discovered the prospective favorable effect of a GP2 peptide-based vaccine. This peptide, combined with a reaction-enhancing adjuvant (GM-CSF), appears to induce an expressed antitumor immune reaction in a subgroup of patients with HER2 (HLA-A*02) breast cancer. The aim of the trial is to compare its efficacy against observation, in an adjuvant context. The mechanism of action and the cure technique are very innovative, as it introduces the study of anti-HER2 vaccines in breast cancer as part of a randomized phase 3 trial. Previous studies on HER2 breast cancer are very encouraging, with a fairly good protection profile, so there are moderate expectations of good luck with this vaccine, of course it requires immediate confirmation through this type of trial.
Dr. Luis de la Cruz Merino is Professor of Medicine, Head of the Clinical Oncology Department at Virgen Macarena University Hospital, Seville, Spain. He specializes in cancer and immunology and is responsible for representing all GEICAM participating PIs from a clinical and immunotherapeutic perspective.
GEICAM’s 38 clinical sites will be indexed in Clinicaltrials. gov with an interactive map and are listed below.
Albacete
Albacete University Hospital Complex
Alicante
Badajoz
University Hospital of Badajoz
Barcelona
Clínica Hospital de BarcelonaHospital del Mar
San Pedro de Alcántara Hospital
Cordova
Reina Sofia University Hospital
Fuenlabrada (Madrid)
Galdacano
Hospital Galdácano-Usánsolo
Granada
San Cecilio Clinical University Hospital
University Hospital of Jaén
Jerez de la Frontera
University Hospital of Jerez de la Frontera
La Laguna (Tenerife)
Lleida
Arnau de Vilanova University Hospital in Lleida
Madrid
Gregorio Marañón General University Hospital 12 de Octubre University Hospital Jiménez Díaz Foundation University Hospital HM Sanchinarro University Hospital Infanta Leonor University Hospital
Puerta de Hierro Majadahonda University Hospital
Malaga
Regional University Hospital of Malaga
Manresa (Barcelona)
Murcia
Morales Meseguer General University Hospital
Virgen de los Ángeles Arrixaca University Clinic
Palma, Mallorca (Balearic Islands)
San Juan (Alicante)
San Juan University Hospital in Alicante
San Sebastian
Donostia University Hospital
General University Hospital of Catalonia – Quirónsalud Group
Santa Cruz of Tenerife
Our Lady of Candelaria University Hospital
Santiago de Compostela
Seville
Virgen del Rocío University HospitalVirgen Macarena University Hospital
Toledo
University Hospital of Toledo
Consortium of General University Hospitals of ValenciaFoundation of the Valencian Institute of OncologyHospital Clínico Universitario de ValenciaHospital Universitario Arnau de Vilanova de Valencia
Saragossa
Miguel Servet University Hospital
About FLAMINGO-01 and GLSI-100
For more information on FLAMINGO-01, visit the company’s website here and Clinicaltrials. gov here. Contact details and an interactive map of most of the interesting clinical sites can be discovered in the “Contacts & Locations” section. Please note that the interactive site map is not visible on mobile screens. Related questions and participation interests can be emailed a:flamingo-01@greenwichlifesciences. com
About the breast and HER2/neu positivity
In the U. S. , one in eight women will develop invasive breast cancer in their lifetime, with an estimated 282,000 new breast cancer patients and 3. 8 million breast cancer survivors in 2021. HER2 (human epidermal expansion receptor 2) is a mobile surface receptor protein that is expressed in a variety of common cancers, aggregating 75% of breast cancers at low (1), intermediate (2), and high (3 or overexpressing) levels.
About Greenwich LifeSciences, Inc.
Disclaimer Regarding Forward-Looking Statements
The statements included in this press release involve “forward-looking statements” that are subject to significant risks and uncertainties. All statements, other than statements of past fact, included in this press release are forward-looking statements. Forward-looking statements included in this press release may be understood by the use of words such as “anticipate,” “believe,” “believe,” “could,” “estimate,” “expect,” “aim,” ” seek”, “possibly”, “could”, “plan”, “potential”, “predict”, “project”, “target”, “objective”, “should”, “will”, “could” or the negative of those terms. words or other similar expressions, not all forward-looking statements involve those words. Forward-looking statements are based on Greenwich LifeSciences Inc. ‘s existing expectations and are subject to inherent uncertainties, hazards and assumptions that are difficult to predict, including statements regarding the expected use of the net proceeds from the public offering; therefore, actual effects would likely differ materially from those expressed or implied by such forward-looking statements. In addition, certain forward-looking statements are based on assumptions about future events that may not prove true. These and other dangers and uncertainties are described in more detail in the segment titled “Risk Factors” of Greenwich LifeSciences’ Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and elsewhere. periodic reports filed with the Securities and Exchange Commission. The forward-looking statements involved in this announcement are made as of this date and Greenwich LifeSciences, Inc. assumes no legal responsibility to update this data unless required by applicable law.
Company ContactSnehal PatelInvestor RelationsOffice: (832) 819-3232Email: info@greenwichlifesciences. com
Greenwich LifeSciences Investor & Public Relations Contact Dave GentryRedChip Companies Inc. Office: 1-800-RED CHIP (733-2447) Email: dave@redchip. com